A Study of PLX2853 in Advanced Malignancies.

Status: Active


The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

Eligibility Criteria

Inclusion Criteria

  • Confirmed diagnosis of one of the following, and must be measurable or evaluable per RECIST 1.1 (solid tumors) or Lugano (NHL):
  • Phase 1b:
  • Histologically confirmed advanced refractory solid tumor that is measurable or evaluable per RECIST 1.1 criteria.
  • Histologically confirmed NHL: diffuse large B-cell lymphoma and follicular lymphoma (Grade 1-3A) that has progressed following at least 1 line of prior anticancer therapy.
  • Phase 2a: Patients with various solid tumors or NHL who have received prior therapy.
  • Age ≥18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Life expectancy ≥3 months in the judgement of the investigator
  • Adequate organ function as appropriate for the disease under study. All screening laboratory tests should be performed within 10 days of treatment initiation.
  • Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at Screening (≤7 days prior to 1st study drug dose) and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.
  • Fertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug.
  • All associated clinically significant drug-related toxicity from previous cancer therapy must be resolved prior to study treatment administration (alopecia is allowed).
  • Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements

Exclusion Criteria

  • Prior exposure to a bromodomain inhibitor, such as OTX-015 or CPI-0610
  • Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade 2
  • Uncontrolled autoimmune hemolytic anemia or thrombocytopenia
  • Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases
  • Known or suspected allergy to the investigational agent or any agent given in association with this trial
  • Clinically significant cardiac arrhythmias including bradyarrhythmias and/or subjects who require anti-arrhythmic therapy (excluding beta blockers or digoxin). Subjects with controlled atrial fibrillation are not excluded.
  • Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption
  • Non-healing wound, ulcer, or bone fracture
  • Subject has known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection or is known to be a carrier of hepatitis B or C.
  • History (within 2 years prior to first study drug administration) of another malignancy unless the malignancy was treated with curative intent and likelihood of relapse is small. Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix may be enrolled.
  • Persistent, unresolved ≥Grade 2 clinically significant drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy) associated with previous treatment
  • Major surgery or significant traumatic injury within 14 days prior to Cycle 1 Day 1
  • Receipt of anti-cancer therapy prior to Cycle 1 Day 1: no chemotherapy, radiation therapy, small molecule tyrosine kinase inhibitor (TKI), or hormonal therapy for the treatment of cancer within 14 days or 5 half-lives (whichever is shorter) of Cycle 1 Day 1. No immune therapy or other biologic therapy (other monoclonal antibodies or antibody-drug conjugates [ADCs]) for the treatment of cancer within 28 days of Cycle 1 Day 1.
  • Subject is receiving systemic steroids at doses greater than the equivalent of prednisone 10 mg daily, with the exception of intermittent use for the treatment of emesis
  • Subject is participating in any other therapeutic clinical study (observational or registry trials are allowed)
  • Female subjects who are pregnant or breast-feeding
  • Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol or would interfere with the study endpoints or the subject's ability to participate in the study in the judgement of the investigator

Locations & Contacts

New York

New York
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase I/II

Trial Type


Lead Organization

Lead Organization
Plexxikon Inc

Trial IDs

Primary ID PLX124-01
Secondary IDs NCI-2018-00860
Clinicaltrials.gov ID NCT03297424